Management of Elevated LDL Particle Number

Understanding LDL Particle Number

Small, dense LDL particles are more susceptible to oxidation and may increase cardiovascular risk more than larger particles 2
In type 2 diabetes, patients often have a higher proportion of smaller, denser LDL particles despite potentially normal LDL-C levels 2

Measure LDL particle number in patients with premature CVD, family history of premature CVD, recurrent CVD despite optimal lipid-lowering therapy, diabetes mellitus, or ≥5% 10-year risk of fatal CVD according to risk algorithms 3
Measure LDL particle number in patients with diabetes mellitus, especially with elevated triglycerides and low HDL 2

The American Diabetes Association recommends limiting saturated fatty acids to <7% of energy intake, limiting trans-fatty acids, restricting dietary cholesterol to <200 mg/day, adding plant stanols/sterols (2 g/day), and increasing soluble fiber intake (10-25 g/day) 1
Promote weight loss through caloric restriction and increased physical activity, and recommend regular physical activity to improve lipid profile and insulin sensitivity 1
Consider adding PCSK9 inhibitors for very high-risk patients not achieving goals with statins and ezetimibe 3
For patients with elevated triglycerides and low HDL-C, consider fibrates or niacin as adjunctive therapy, and monitor for potential drug interactions when combining with statins 1
For patients with very high triglycerides (>1000 mg/dL), restrict all types of dietary fat, and consider omega-3 fatty acids/fish oils, but monitor LDL-C as they may increase levels 5

Assess lipid profile, including LDL particle number if available, every 3-6 months until target is achieved, and every 6-12 months after reaching target 1
Consider non-HDL cholesterol as a surrogate target when LDL particle number measurement is unavailable 6
Target LDL-C levels <70 mg/dL for very high-risk patients, which typically corresponds to lower LDL particle numbers 6

LDL particle number measurement is not standardized across all laboratories, which may affect result interpretation 3
Some patients may have normal LDL-C but elevated LDL particle numbers, especially those with metabolic syndrome or diabetes 2
When using combination therapy, monitor for potential adverse effects, particularly myopathy with statin-fibrate combinations 1